A Phase I, dose escalation trial of Recombinant Modified Vaccinia Ankara (MVA)-based vaccine encoding Epstein-Barr virus target antigens.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine-EBV (Primary)
- Indications Epstein-Barr virus infections
- Focus Adverse reactions; Pharmacodynamics
- 28 Feb 2012 Biomarkers information updated
- 27 Feb 2012 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 27 Feb 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.